Latest market price
21.60
+0.11+0.51%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -124.78 | Insider Own | 3.19% | Shs Outstand | 61.74M | Perf Week | 1.60% |
| Market Cap | 1.33B | Forward P/E | — | EPS next Y | -2.11 | Insider Trans | 0.62% | Shs Float | 40.89M | Perf Month | 4.60% |
| Enterprise Value | 801.49M | PEG | — | EPS next Q | -0.48 | Short Float | 12.60% | Perf Quarter | -28.05% | ||
| Income | -263.00M | P/S | — | EPS this Y | — | Short Ratio | 9.83 | Perf Half Y | -16.70% | ||
| Sales | 0.00 | P/B | 2.61 | EPS next Y | — | ROA | -48.35% | Short Interest | 5.15M | Perf YTD | -6.13% |
| Book/sh | 8.26 | P/C | 2.50 | EPS next 5Y | — | ROE | -82.56% | 52W High | 38.33 -43.65% | Perf Year | 193.88% |
| Cash/sh | 8.63 | P/FCF | — | EPS past 3/5Y | — | ROIC | -52.44% | 52W Low | 4.95 336.36% | Perf 3Y | 57.09% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 7.78% 7.16% | Perf 5Y | -74.44% |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 1.51 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 19.73 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 50.52 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 19.73 | EPS Q/Q | 85.00% | SMA20 | 5.35% | Beta | 1.48 | Target Price | 52.50 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | — | SMA50 | -7.49% | Rel Volume | 0.94 | Prev Close | 21.49 |
| Employees | 7 | LT Debt/Eq | 0.00 | Earnings | Nov 05 | SMA200 | -15.77% | Avg Volume | 530.09K | Price | 21.60 |
| IPO Date | Oct 29, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 5.11% — | Net Debt/EBITDA | — | Volume | 497,323 | Change | 0.51% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-25-26 | Reiterated | H.C. Wainwright | Buy | $45 → $60 |
| Sep-25-26 | Reiterated | Guggenheim | Buy | $60 |
| Jul-30-26 | Reiterated | Wedbush | Outperform | $35 → $40 |
| Jul-26-26 | Initiated | Jefferies | Buy | $50 |
| Jun-11-26 | Initiated | H.C | Buy | $45 |
| May-28-26 | Initiated | Wedbush | Outperform | $35 |
| Apr-23-26 | Initiated | RBC Capital | Outperform | $40 |
Latest News· Times ET
Oct-21-26
Oct-21-2606:12AM
Oct-10-26
Oct-03-26
Oct-03-2605:01AM
Oct-02-26
Oct-02-2607:59AM
Sep-29-26
Sep-28-26
Sep-28-2609:08AM
Sep-25-26
Sep-15-26
Sep-03-26
Sep-03-2608:00AM
Aug-12-26
Aug-12-2609:03AM
Aug-05-26
Aug-05-2608:00AM
Aug-03-26
Aug-03-2604:01PM
Jul-30-26
Jul-30-2605:42AM
Company
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | 1 | — | — | — | — | — | |
| Gross Profit | 0 | 0 | 0 | -1 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 22 | 10 | 10 | 12 | — | — | — | — | — | |
| Research and Development | 249 | 201 | 6 | 24 | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 1 | 0 | — | — | — | — | — | |
| Operating Income | -271 | -211 | -17 | -36 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 8 | 1 | -5 | -2 | — | — | — | — | — | |
| Net Income Before Taxes | -263 | -210 | -21 | -38 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -263 | -210 | -21 | -38 | — | — | — | — | — | |
| Net Income From Continuing Operations | -263 | -210 | -21 | -38 | — | — | — | — | — | |
| Net Income | -263 | -210 | -21 | -38 | — | — | — | — | — | |
| EPS (Recurring) | -124.78 | -152.99 | -18.53 | -36.08 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -124.78 | -152.99 | -18.53 | -36.08 | — | — | — | — | — | |
| EPS (Diluted) | -124.78 | -152.99 | -18.53 | -36.08 | — | — | — | — | — | |
| EBITDA | -267 | -210 | -21 | -38 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 61 | 1 | 1 | 1 | — | — | — | — | — | |
| Market Capitalization | 1,318 | 23 | 5 | 18 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Jarrett Jennifer | Director, President and CEO | Sep 25 '26 | Buy | 20.23 | 12,500 | 252,875 | 512,500 | Sep 28 |
| Winslow Garrett | General Counsel | Jul 06 '26 | Sale | 29.98 | 245 | 7,345 | 2,289 | Jul 07 |
| Winslow Garrett | General Counsel | Jul 03 '26 | Option Exercise | 0.00 | 680 | 0 | 2,534 | Jul 07 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.